Certara, Inc. · NASDAQ:CERT

Certara — Technical Presentation (January 2014)

18 slides from Certara's technical presentation, Jan 28, 2014

  1. Slide 1: Phoenix QT+ ― A New Tool to Assess Cardiac Safety

    Phoenix QT+ ― A New Tool to Assess Cardiac Safety Christine Garnett, PharmD January 28, 2014

  2. Slide 2: Agenda

    Agenda • Overview of QT+ (10 min) • Phoenix QT+ for analysis of a Thorough QT study (30 min) • Q&A (10 min) © Copyright 2012 Certara, L.P. All rights reserved. 2

  3. Slide 3: Regulatory Expectations

    Regulatory Expectations © Copyright 2012 Certara, L.P. All rights reserved. 3

  4. Slide 4: Centerpiece of ICH E14: Thorough QT Study

    Centerpiece of ICH E14: Thorough QT Study • Determine whether the drug has a threshold pharmacologic effect on cardiac repolarization, as detected by QTc prolongation – Regulatory threshold is around 5 ms as evidenced by an upper bound of the 95% CI around the mean effect of 10 ms • Randomized, blin

  5. Slide 5: QT Evaluation in Drug Development

    QT Evaluation in Drug Development QT/QTc evaluation occurs throughout Clinical Development Phase Phase Phase FDA Preclinical 2 1 3 Filing Routine - ECGs TQT Nonclinical S7B & Phase 1 ECGs study Intensive  Clinical + ECGs Pharmacology  Clinical doses © Copyright 2012 Certara, L.P. All rights reserv

  6. Slide 6: Phoenix QT+

    Phoenix® QT+ • Provides data processing, statistical and modeling tools to address whether a drug prolongs cardiac repolarization as specified in ICH E14 guidelines • Used to analyze ECG (QT, QRS, PR and HR) and PK data collected in clinical studies to support regulatory submissions • Thorough QT/QT

  7. Slide 7: Phoenix QT+ Workflow Objects

    Phoenix® QT+ Workflow Objects Heart Rate Correction QT Transformations Central Tendency Outlier Analysis Exploratory Plots CQTc © Copyright 2012 Certara, L.P. All rights reserved. 7

  8. Slide 8: Phoenix QT+ Process

    Phoenix QT+ Process Prepare/ Analyze Input Data Report Visualize Data Data Heart Rate Central Correction Tendency Phoenix QT Phoenix Input/ CQTc Transforms Tables Output Exploratory Outliers Plots © Copyright 2012 Certara, L.P. All rights reserved. 8

  9. Slide 9: QT+ for Analysis of a TQT Study

    QT+ for Analysis of a TQT Study © Copyright 2012 Certara, L.P. All rights reserved.

  10. Slide 10: Example Problem: Is ECG monitoring for NuDrug needed in late phase studies?

    Example Problem Is ECG monitoring for NuDrug needed in late phase clinical studies? • NuDrug is a new atypical antipsychotic being developed for the treatment of schizophrenia. • In safety pharmacology studies, NuDrug was found to inhibit the hERG channel at 10μM. No effect on Ca2+ and Na+ channels.

  11. Slide 11: TQT Study Design

    TQT Study Design • 4-period, single-dose, crossover study – NuDrug 20 mg (higher than therapeutic dose) – NuDrug 100 mg (supratherapeutic dose) – Moxifloxacin 400 mg (positive control) – Placebo • 24 subjects • ECGs and PK samples collected pre-dose (-2, -1, -0.5 h) and at 1, 2, 2.5, 3, 4, 6,10, 12

  12. Slide 12: Key Questions for TQT Study Analysis

    Key Questions for TQT Study Analysis • Which heart rate correction method should be used for evaluation? • Did the study demonstrate assay sensitivity? • Does NuDrug prolong the QTc interval? If so, at what dose level? • Are patients at risk for QTc prolongation? © Copyright 2012 Certara, L.P. All r

  13. Slide 13: Phoenix Project

    Phoenix Project © Copyright 2012 Certara, L.P. All rights reserved.

  14. Slide 14: Key Questions for TQT Study Analysis – No QTcF >480 ms, No ΔQTcF >30 ms

    Key Questions for TQT Study Analysis • Which heart rate correction method should be used for evaluation? – No heart rate changes for NuDrug – No dependency of QTcF on heart rate – QTcF selected for further analysis • Did the study demonstrate assay sensitivity? – Yes, lower 90% CI excluded 5 ms for

  15. Slide 15: Key Questions for TQT Study Analysis

    Key Questions for TQT Study Analysis • Are patients at risk for QTc prolongation? – Clinical pharmacology background • Linear PK with t1/2 of 14 h and accumulates 1.75-fold with once daily administration. It’s primarily metabolized by CYP3A4 to an inactive metabolite. With ketoconazole, Cmax and AUC

  16. Slide 16: Phoenix Project

    Phoenix Project © Copyright 2012 Certara, L.P. All rights reserved.

  17. Slide 17: Key Questions for TQT Study Analysis

    Key Questions for TQT Study Analysis • Are patients at risk for QTc prolongation? – No, patient under high exposure scenario of (5 mg with CYP3A4 inhibition) are not expected to have clinically significant QTcF prolongation. • At 5 mg/day at steady-state, mean ΔΔQTcF is <2 ms • With metabolic inhibi

  18. Slide 18: Phoenix QT+

    Phoenix QT+ • User can perform a comprehensive analysis of ECG data from cardiac safety studies using six new Phoenix QT+ objects. – No programming – Time saving – Outputs (plots and worksheets) can be used in reports • Phoenix QT+ shows workflows visually. Easy to share data, analysis and results a

Certara — Technical Presentation (January 2014) on 6ix